New drug combo aims to shrink aggressive prostate tumors before surgery
NCT ID NCT00329043
First seen Nov 10, 2025 · Last updated Jun 19, 2026 · Updated 35 times
Summary
This phase 2 trial is testing whether adding the drug sunitinib to standard hormone therapy can shrink or control high-risk prostate cancer before the prostate is removed. About 64 men with localized but aggressive prostate cancer will receive sunitinib pills plus a hormone blocker for up to 3 months, then undergo surgery. The main goal is to see if the cancer completely disappears in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sunitinib malate (Sutent) plus a hormone blocker (LHRH agonist like Lupron)
What this could lead to
If it works, this combination could help shrink aggressive prostate tumors before surgery, potentially lowering the risk of cancer coming back.
What could go wrong
This is a small, early-phase trial (64 people) with no control group, so results may not apply broadly. Sunitinib can cause side effects like fatigue, high blood pressure, and liver issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.